20170625 (Vesalius): Phase III
Treating: Coronary Heart Disease
Investigator(s): PI: Dr. Libby Lake, Sub-I: Ellen Sparks, PA-C
Indication: Reduce the risk of Coronary Heart Disease (CHD) death, myocardial infarction (MI), stroke, and ischemia-driven arterial revascularization in adults at high risk of cardiovascular events without prior MI or stroke
Status: Open/Currently Enrolling
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Rike Without Prior Myocardial Infarction or Stroke
ATB200-02: Phase I/II
Treating: Pompe Disease
Investigator(s): PI: Dr. Karl Guter, Sub-I: Dr. Thomas Warr
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease
CAIN457H2315: Phase III
Treating: Axial Spondyloarthritis
Investigator(s): PI: Dr. Libby Lake, Sub-I: Dr. Karl Guter
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis
CAIN457K2340: Phase III
Treating: Axial Spondyloarthritis
Investigator(s): PI: Dr. Karl Guter, Sub-I: Dr. Libby Lake
Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis
D169CC00001 (Deliver-HF): Phase III
Treating: Heart Failure
Investigator(s): PI: Dr. Jorge Castriz, Sub-I: Ellen Sparks, PA-C
Status: Open/Currently enrolling
An international, double-blind, randomized, placebo-controlled phase III study to evaluate the effect of Dapagliflozin on reducing CV death or worsening heart failure in patient with heart failure with preserved ejection fraction (HFpEF)
EFC14828 (Amplitude-O): Phase III
Treating: Diabetes
Investigator(s): PI: Dr. Thomas Warr, Sub-I: Dr. Libby Lake
Status: Open/Currently Not Enrolling
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk
I8F-MC-GPGN (SURPASS-CVOT): Phase III
Investigator(s): PI: Dr. Libby Lake, Sub-I: McKinley Hallfrisch, PA-C
Studying: The effect of Tirzepatide vs. Dulaglutide on major cardiovascular events in patients with Type 2 diabetes.
Status: Open/Currently Enrolling
